[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362237-105":59,"doc-detail-362237-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-clinical-oncology-outcomes-associated-with-the-accelerated-approval-pathway","Real-World Clinical Oncology Outcomes - Associated with the Accelerated Approval Pathway","","The accelerated approval (AA) pathway speeds access to treatments for patients with unmet medical needs, yet its real-world impact remains undercharacterized. This nationwide EHR-derived deidentified study evaluated real-world progression-free survival (rwPFS) and overall survival (OS) for AA drugs versus non-AA products with the same indication in solid tumors from 2011–2023. Across 23 AA indications, 83% showed verified clinical benefit and 17% were withdrawn. Most indications improved rwPFS or OS, with population-level gains estimated in rwPFLYs and LYs, supporting substantial US health benefits.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-clinical-oncology-outcomes-associated-with-the-accelerated-approval-pathway/362237/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-clinical-oncology-outcomes-associated-with-the-accelerated-approval-pathway/362237.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question did the study address about the accelerated approval (AA) pathway?","Question",{"text":112,"@type":113},"It assessed real-world clinical outcomes associated with the AA period and compared AA drugs with non-AA products sharing the same indication in solid tumor cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes measured in the real-world setting?",{"text":117,"@type":113},"The study used an EHR-derived deidentified database and evaluated real-world progression-free survival (rwPFS) and overall survival (OS), alongside population-level health impacts.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about clinical benefit and market withdrawals across AA indications?",{"text":121,"@type":113},"Among 23 AA indications, 83% had clinical benefit verified at study completion, while 17% were withdrawn from the market.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362237,1790576917,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0225](https://doi.org/10.1158/2767-9764.CRC-25-0225)  OPEN ACCESS  \nReal-World Clinical Oncology Outcomes   \nAssociated with the Accelerated Approval Pathway  \nTu My To1, Stacey Kowal1, James D. Chambers2, and William B. Wong1  \n􀀶  \nABSTRACT  \nThe accelerated approval (AA) pathway expedites treatment access for patients with unmet medical needs. However, evidence on the program’s impact is lacking. This study assessed real-world clinical outcomes for AA drugs in solid tumor cancers. A nationwide electronic health record (EHR)-derived deidentified database was utilized to explore the impact of the AA pathway in patients with selected solid tumors from 2011 to 2023. Included patients received AA or non-AA products with the same indication. Outcomes were real-world progression-free survival (rwPFS) and overall survival (OS) . Population-level health impacts were estimated via market share and real-world progression-free life years (rwPFLYs) and life years (LYs). Twenty-three AA indications were studied. At study completion, 83% of indications had their clinical benefit verified, whereas 17% had been withdrawn from the market. Overall, 78% of indications demonstrated significant improvements in rwPFS or OS, whereas none reported significantly worse rwPFS versus controls. In total, 44% and 48% of indications had >30% rwPFS and OS improvement, respectively. More indications with sample sizes > 100 in the AA cohort demonstrated  \nsignificant rwPFS gains [80%(12/15)] versus cohorts \u003C100 [38%(3/8)] . An estimated 118,107 patients received AA drugs during their AA window, resulting in 56,399 rwPFLYs and 50,848 LYs gained. Most solid tumor AA indications were associated with improved clinical outcomes, providing substantial US population-level health gains. This EHR analysis provides insight into whether the AA pathway appropriately targets promising beneficial therapies. Expanding beyond randomized controlled trial evidence and conventional primary endpoints may be necessary to verify clinical benefit, particularly in rare tumors.  \nSignificance: This study (the first examining the real-world outcomes associated with the AA period) found improved clinical outcomes for most AA drugs studied compared with existing treatments in solid tumor cancers. The improvements observed suggest potential health improvements at the US population level and the possibility of the need to look beyond randomized controlled evidence and traditional primary endpoints to verify the clinical benefit of AA drugs for relatively rare conditions.  \nIntroduction  \nAccess to medicines in the United States is granted following regulatory approval from the US Food and Drug Administration (FDA), which considers evidence on the safety and efficacy of new drugs based on high-quality clinical data. The FDA’s accelerated approval (AA) pathway was created to expedite access to new treatments with potential benefits over available treatments in serious and life-threatening conditions ( 1, 2) . The AA pathway allows for approval based on a surrogate endpoint, defined as reasonably likely to predict a drug’s clinical benefit (3) .  \n1Genentech, Inc, South San Francisco, California. 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.  \nCorresponding Author: William B. Wong, Genentech, Inc., 1 DNA Way, South San  \nFrancisco, [CA 94080. E-mail:](CA 94080. E-mail: wong.william@gene.com)[ wong.william@gene.com](CA 94080. E-mail: wong.william@gene.com)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0225  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2025 The Authors; Published by the American Association for Cancer Research  \nUnlike traditional approval pathways that rely on randomized controlled trial (RC","cbCaieFMwxafLfSl","https://ap.wps.com/l/cbCaieFMwxafLfSl","pdf",2003548,"English","# Introduction\n## Methods and study design\n## Results and population-level impact\n## Discussion and significance","[{\"question\":\"What question did the study address about the accelerated approval (AA) pathway?\",\"answer\":\"It assessed real-world clinical outcomes associated with the AA period and compared AA drugs with non-AA products sharing the same indication in solid tumor cancers.\"},{\"question\":\"How were outcomes measured in the real-world setting?\",\"answer\":\"The study used an EHR-derived deidentified database and evaluated real-world progression-free survival (rwPFS) and overall survival (OS), alongside population-level health impacts.\"},{\"question\":\"What did the study find about clinical benefit and market withdrawals across AA indications?\",\"answer\":\"Among 23 AA indications, 83% had clinical benefit verified at study completion, while 17% were withdrawn from the market.\"}]","Real-World Clinical Oncology Outcomes - Associated with the Accelerated Approval Pathway | PDF",1790146867,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09ab43e59169b90a3d4d7337fb40b9b3.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/916023f81adf3bdae2038b30561b0a86.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fae37baa2c29dd51e7408b4b8cde4fc7.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a07f2e29147d3b1f511c7c09bc0e798.webp",980,1259]